PMUC1CALLO-1 is under clinical development by Poseida Therapeutics and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PMUC1CALLO-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PMUC1CALLO-1 overview

P-MUC1CALLO-1 is under development for the treatment of solid tumors derived from epithelial cells tumors including triple-negative breast cancer, renal cancer, ovarian cancer, non-small cell lung cancer, esophageal cancer, gastric cancer, pancreatic cancer and colorectal cancers. It comprises of allogeneic stem memory T cells (Tscm), genetically engineered to express chimeric antigen receptor (CAR). It acts by targeting the cells expressing mucin1. The therapeutic candidate is being developed based on Piggybac DNA modification system and CAS Clover gene-editing technology.

Poseida Therapeutics overview

Poseida Therapeutics is a biopharmaceutical company. It harnesses its proprietary gene engineering platform, to develop next generation cell and gene therapeutics to treat solid tumors and hematological malignancies. The company is investigating its lead product candidate P-BCMA-101, an autologous CAR-T therapy against refractory multiple myeloma. It is also evaluating P-PSMA-101 and P-PSMA-ALL01, allogeneic chimeric antigen receptors for the treatment of prostate cancer; and Dual car (CD19/CD20) targeting solid tumor. Poseida Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of PMUC1CALLO-1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.